Cart
×
Entrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45
Entrada trial skipping exon 45 CureDuchenne provided early funding to Entrada Therapeutics, who has announced that they received authorization in the United Kingdom (UK) to initiate a Phase 1/2 multiple […]
Individual with Duchenne dies from acute liver failure after gene therapy treatment
Sarepta Therapeutics has shared that a young man with Duchenne passed away following treatment with ELEVIDYS, an AAV-delivered micro-dystrophin gene therapy. Sarepta has shared that the individual suffered from acute […]
2025 MDA Clinical & Scientific Conference Updates
2025 MDA Conference Updates We’re at the 2025 MDA Clinical & Scientific Conference this week and are pleased to share research updates from companies presenting on the latest advancements in Duchenne muscular […]
Capricor announces that individuals with Duchenne treated with deramiocel had significantly less progression in loss of upper limb function
Capricor Therapeutics received early funding from CureDuchenne, and today Capricor released new data reporting that individuals treated with deramiocel over three years experienced an average decline in Performance of the […]
Dyne announces new long-term data from DMD clinical trial skipping Exon 51
CureDuchenne provided early funding to Dyne Therapeutics, and is pleased to share that Dyne has released new long-term data from the DELIVER trial in individuals amenable to skipping Exon 51. […]
Avidity announces positive topline data from DMD clinical trial skipping exon 44
CureDuchenne provided early funding to Avidity Biosciences, and are pleased to share they have released positive topline data from the EXPLORE44 trial in individuals amenable to skipping exon 44. Data […]
PepGen is temporarily pausing their Phase 2 CONNECT2-EDO51 study in the UK
PepGen, which received early funding from CureDuchenne, announced that they are temporarily pausing their CONNECT2 study in the UK in order to focus resources and first review data from the […]
Edgewise’s recent business highlights from 2024 include advances in their clinical trials in both Duchenne and Becker
CureDuchenne provided early funding to Edgewise Therapeutics, and we are pleased with their progress as recently shared in their fourth quarter and full year 2024 reports. In Becker muscular dystrophy, […]